FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 743 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 Anal Cancer Incidence and Deaths Are Rising in the United States December 19, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine September 22, 2022 The award-winning researcher behind next generation sequencing October 15, 2021 Load more HOT NEWS What Caregivers Should Know About End-of-Life Care Issues for People With... Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... Firefighter Advocates For Men’s Health While He Battles Breast Cancer In...
